POLYMED - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 3.5

📊 Analysis: POLYMED is trading at ₹1,810, below both 50 DMA (₹1,917) and 200 DMA (₹2,061), reflecting short-term weakness. RSI at 35.0 indicates oversold conditions, while MACD (-23.2) confirms bearish momentum. Intraday volume (96,080) is higher than the 1-week average (51,247), suggesting active participation today. Fundamentals are moderate with ROCE (18.2%) and ROE (14.2%), though valuations remain expensive (P/E 52.6 vs industry PE 41.5). Intraday trades should be defensive but can benefit from oversold recovery setups.

💡 Optimal Buy Price: ₹1,800–₹1,815 (near support zone).

🎯 Profit-Taking Levels: ₹1,840 – ₹1,860 (short-term resistance).

🛡️ Stop-Loss: ₹1,785 (below intraday support).

⏱️ Exit Strategy if Already Holding: Exit intraday if price fails to sustain above ₹1,810 with weakening momentum. If RSI drops below 34 and MACD remains negative, consider closing positions near ₹1,800–₹1,810. If momentum improves with volume pickup, hold until ₹1,840–₹1,860.

Positive

• 📈 ROCE (18.2%) and ROE (14.2%) show moderate efficiency.
• 💡 DII holding increased (+1.81%), reflecting domestic investor confidence.
• ⚡ Debt-to-equity 0.08 indicates strong balance sheet stability.
• 📊 EPS ₹34.4 supports earnings strength.

Limitation

• 📉 Current price below DMA 50 & DMA 200, reflecting bearish trend.
• 📊 High P/E (52.6) vs industry PE (41.5) indicates premium valuation.
• 📉 Dividend Yield 0.19% is negligible.

Company Negative News

• ⚠️ FII holding reduced (-1.64%), showing foreign investor caution.
• 📉 Weak 52-week performance with only 3.71% gain.

Company Positive News

• ✅ Quarterly PAT improved slightly from ₹87.9 Cr. to ₹89.0 Cr.
• 💡 DII holding increased, supporting domestic sentiment.

Industry

• 🏭 Industry PE at 41.5 vs stock PE 52.6, showing premium valuation.
• 📊 Medical devices sector remains resilient with long-term demand drivers.

Conclusion

⚖️ POLYMED shows moderate fundamentals but weak short-term technicals. Intraday traders should be cautious, buying near support (₹1,800–₹1,815) with tight stop-losses. Upside is possible toward ₹1,840–₹1,860 if momentum improves. Long-term investors may remain cautious due to premium valuations, but intraday trades can be attempted defensively today.

Would you like me to extend this into a peer benchmarking overlay comparing POLYMED with other medical device sector stocks, or prepare a sector rotation basket scan to highlight stronger intraday momentum candidates?